A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137
administered intravenously in participants with metastatic or unresectable advanced solid
malignancies.